Dyspnea during thalidomide treatment for advanced ovarian cancer.

about

Pulmonary toxicity from novel antineoplastic agents.Thalidomide-Related Eosinophilic Pneumonia: A case report and brief literature review.Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature.

P2860

Q36314452-7C7C7097-54DF-40C2-905E-A01DDFAB0D2E Q37263330-943B70B3-8E29-4998-A314-B8CD84D06781 Q41619260-5D1F99DD-7197-488F-963B-8DACFC741066

P2860

Dyspnea during thalidomide treatment for advanced ovarian cancer.

Item

http://www.wikidata.org/entity/Q36089929

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Dyspnea during thalidomide treatment for advanced ovarian cancer.

@ast

Dyspnea during thalidomide treatment for advanced ovarian cancer.

@en

type

Item

label

Dyspnea during thalidomide treatment for advanced ovarian cancer.

@ast

Dyspnea during thalidomide treatment for advanced ovarian cancer.

@en

prefLabel

Dyspnea during thalidomide treatment for advanced ovarian cancer.

@ast

Dyspnea during thalidomide treatment for advanced ovarian cancer.

@en

P1476

Dyspnea during thalidomide treatment for advanced ovarian cancer.

@en

P2093

Don S Dizon

http://www.w3.org/2001/XMLSchema#string

Mary E Gordinier

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

A method for estimating the probability of adverse drug reactions

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

[Lung toxicity due to thalidomide]

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.

Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.

P304

962-965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1E608

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15811905

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

thalidomide

Dyspnea during thalidomide treatment for advanced ovarian cancer.

about

P2860

P2860

Dyspnea during thalidomide treatment for advanced ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921